Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
Human papilloma virus type 57 (HPV 57) antigen in combination with Canada antigen elicits L1-specific T-cell responses and complete resolution of warts More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 40 pages - $500
Apr 2011 - 24 pages - $1,000
Aug 2009 - 180 pages - $3,500
Mar 2011 - 32 pages - $250
Nov 2011 - 7 pages - $3,835
Dec 2010 - 48 pages - $1,000
Jun 2006 - 1458 pages - $2,495
Oct 2009 - 17 pages - $500
May 2009 - 131 pages - $3,800
Jan 2010 - $75
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us